Table 4.

Distribution of CD58 rs12044852 in patients with SSc and healthy controls.

	No.	Genotype, %			A Allele, %	Allelic Association
		AA	AC	CC		p	Corrected padj	OR (95% CI)
French Caucasian
Controls	995	1.2	16.5	82.3	9.5
Patients with SSc	1015	1.0	18.5	80.5	10.3	0.40	NA	1.1 (0.89–1.3)
Limited SSc	640	0.8	19.4	79.8	10.5	0.34	NA	1.1 (0.89–1.4)
Diffuse SSc	316	1.3	17.4	81.3	10.0	0.70	NA	1.1 (0.79–1.4)
Autoantibodies
Anti-centromere	373	0.6	18.2	81.2	9.7	0.87	NA	1.0 (0.77–1.4)
Anti-topoisomerase I	247	2.0	17.8	80.2	10.9	0.32	NA	1.2 (0.85–1.6)
US Caucasian
Controls	691	1.6	20.1	78.3	23.3
Patients with SSc	1038	0.9	16.6	82.6	18.3	0.017	0.051	0.76 (0.6–0.96)
Limited SSc	600	1.0	17.0	82.0	19.0	0.08	0.8	0.80 (0.6–1.03)
Diffuse SSc	383	0.5	15.7	83.8	16.7	0.017	0.17	0.69 (0.5–0.95)
Autoantibodies
Anti-centromere	293	1.0	14.3	84.6	16.4	0.023	0.23	0.68 (0.5–0.96)
Anti-topoisomerase I	172	1.7	14.5	83.7	18.0	0.16	NA	0.75 (0.5–1.1)